There is only one FDA-approved, PCR-based multiplex testing kit, manufactured by Myriad Genetic Laboratories (BRACAnalysis CDx), which specifically targets BRCA1 and BRCA2 markers for breast, ovarian, and pancreatic cancers (https://myriad.com/genetic-tests/bracanalysiscdx-germline-test/). This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.